Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
WST logo WST
Upturn stock ratingUpturn stock rating
WST logo

West Pharmaceutical Services Inc (WST)

Upturn stock ratingUpturn stock rating
$246.2
Last Close (24-hour delay)
Profit since last BUY-6.49%
upturn advisory
Consider higher Upturn Star rating
BUY since 15 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: WST (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

13 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $316.36

1 Year Target Price $316.36

Analysts Price Target For last 52 week
$316.36 Target price
52w Low $187.09
Current$246.2
52w High $351.24

Analysis of Past Performance

Type Stock
Historic Profit -22.51%
Avg. Invested days 28
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 17.70B USD
Price to earnings Ratio 36.91
1Y Target Price 316.36
Price to earnings Ratio 36.91
1Y Target Price 316.36
Volume (30-day avg) 13
Beta 1.05
52 Weeks Range 187.09 - 351.24
Updated Date 08/15/2025
52 Weeks Range 187.09 - 351.24
Updated Date 08/15/2025
Dividends yield (FY) 0.34%
Basic EPS (TTM) 6.67

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-07-23
When Before Market
Estimate 1.51
Actual 1.84

Profitability

Profit Margin 16.48%
Operating Margin (TTM) 20.87%

Management Effectiveness

Return on Assets (TTM) 10.53%
Return on Equity (TTM) 17.72%

Valuation

Trailing PE 36.91
Forward PE 38.46
Enterprise Value 17497183415
Price to Sales(TTM) 5.98
Enterprise Value 17497183415
Price to Sales(TTM) 5.98
Enterprise Value to Revenue 5.91
Enterprise Value to EBITDA 23.03
Shares Outstanding 71907296
Shares Floating 71388873
Shares Outstanding 71907296
Shares Floating 71388873
Percent Insiders 0.61
Percent Institutions 97.94

ai summary icon Upturn AI SWOT

West Pharmaceutical Services Inc

stock logo

Company Overview

overview logo History and Background

Founded in 1923, West Pharmaceutical Services has evolved from a small manufacturer of rubber closures for medicinal products to a global leader in innovative solutions for injectable drug delivery. Key milestones include the development of new closure technologies and expansion into device manufacturing and contract manufacturing services.

business area logo Core Business Areas

  • Proprietary Products: Develops, manufactures, and sells stoppers, plungers, seals, and other components for injectable drug packaging and delivery systems.
  • Contract-Manufactured Products: Provides contract manufacturing services for medical devices, including wearable injectors and auto-injectors.

leadership logo Leadership and Structure

The leadership team is headed by the CEO, with a structure encompassing various functional departments such as operations, R&D, sales, and finance. Board of Directors provides oversight.

Top Products and Market Share

overview logo Key Offerings

  • Elastomeric Closures: Provides various elastomeric closures that ensure drug integrity and purity. West is a market leader in this space, competing with Datwyler. Estimated market share is approximately 20-25% of the global elastomeric closure market for injectable drugs. Revenue is approximately 1.5 Billion. Competitors: Datwyler Holding Inc. (DWTN.SW), AptarGroup, Inc (ATR).
  • Drug Delivery Devices: Designs and manufactures prefilled syringes, auto-injectors, and wearable injectors. Competing with companies like BD and Novo Nordisk in specific device markets. High-growth business driven by the increasing demand for self-administration of medications. Revenue is approximately 0.5 Billion. Competitors: Becton, Dickinson and Company (BDX), Novo Nordisk (NVO).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical packaging and drug delivery market is experiencing growth driven by factors such as the increasing demand for injectable drugs, biologics, and personalized medicine, as well as technological advancements in drug delivery systems.

Positioning

West Pharmaceutical Services Inc. is a leading player in the market due to its long-standing expertise, strong customer relationships, and innovative product offerings. Its competitive advantage lies in its ability to provide comprehensive solutions for drug packaging and delivery.

Total Addressable Market (TAM)

The total addressable market for pharmaceutical packaging and drug delivery is estimated to be over $100 billion. West is well-positioned to capture a significant share of this market through its established presence and innovative products.

Upturn SWOT Analysis

Strengths

  • Strong brand reputation
  • Extensive product portfolio
  • Long-standing customer relationships
  • Innovative technology
  • Global presence

Weaknesses

  • Dependence on the pharmaceutical industry
  • Exposure to raw material price fluctuations
  • Competition from larger players
  • High capital expenditures

Opportunities

  • Growing demand for biologics and injectable drugs
  • Expansion into emerging markets
  • Development of new drug delivery technologies
  • Increasing adoption of self-administration of medications
  • Strategic acquisitions

Threats

  • Intense competition
  • Regulatory changes
  • Product liability claims
  • Economic downturns
  • Supply chain disruptions

Competitors and Market Share

competitor logo Key Competitors

  • DWTN.SW
  • ATR
  • BDX

Competitive Landscape

West competes on product quality, innovation, and customer service. It has a strong advantage in its established customer relationships and specialized expertise, but faces competition from larger, more diversified companies.

Major Acquisitions

Medimop Medical Projects Ltd.

  • Year: 2017
  • Acquisition Price (USD millions): 147.5
  • Strategic Rationale: Expanded Westu2019s self-injection and drug delivery capabilities.

Growth Trajectory and Initiatives

Historical Growth: West Pharmaceutical Services Inc. has experienced consistent revenue growth over the past decade, driven by increasing demand for its products and services.

Future Projections: Analysts project continued revenue growth for West Pharmaceutical Services Inc. in the coming years, driven by factors such as the aging population, the increasing prevalence of chronic diseases, and the development of new injectable drugs.

Recent Initiatives: Recent strategic initiatives include expanding manufacturing capacity, investing in R&D, and pursuing acquisitions to strengthen its market position.

Summary

West Pharmaceutical Services is a well-established company with a strong market position in the pharmaceutical packaging and drug delivery industry. Its focus on innovation and customer relationships is working well, contributing to consistent revenue growth. However, competition remains intense, and the company needs to carefully manage its exposure to raw material price fluctuations and potential regulatory changes. The company should focus on further innovation in injectable drug delivery to stay ahead.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (10-K, 10-Q), Investor Presentations, Analyst Reports, Market Research Reports
  • West Pharmaceutical Services Website

Disclaimers:

The data and analysis provided are based on available information and are subject to change. This is not financial advice. Consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About West Pharmaceutical Services Inc

Exchange NYSE
Headquaters Exton, PA, United States
IPO Launch date 1978-01-13
Non-Independent Chair of the Board, President & CEO Mr. Eric M. Green
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 10600
Full time employees 10600

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.